EMEA-001525-PIP02-21
Key facts
| Active substance |
Human alpha1-proteinase inhibitor
|
| Therapeutic area |
Pneumology-allergology
|
| Decision number |
P/0499/2021
|
| PIP number |
EMEA-001525-PIP02-21
|
| Pharmaceutical form(s) |
All pharmaceutical forms
|
| Condition(s) / indication(s) |
Treatment of emphysema secondary to congenital deficiency of alpha-1 antitrypsin
|
| Route(s) of administration |
All routes of administration
|
| Contact for public enquiries |
Kamada Ireland Limited
Email: oritp@kamada.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|